Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Principal Financial Group Inc. purchased a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,294 shares of the company’s stock, valued at approximately $267,000.

A number of other institutional investors have also recently modified their holdings of YMAB. Massachusetts Financial Services Co. MA lifted its holdings in Y-mAbs Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after acquiring an additional 2,760 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at about $44,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the period. Rice Hall James & Associates LLC boosted its holdings in Y-mAbs Therapeutics by 4.2% during the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after buying an additional 3,589 shares in the last quarter. Finally, FMR LLC grew its position in Y-mAbs Therapeutics by 23.1% during the third quarter. FMR LLC now owns 36,416 shares of the company’s stock worth $479,000 after buying an additional 6,822 shares during the period. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Stock Down 4.4 %

Shares of Y-mAbs Therapeutics stock opened at $7.81 on Tuesday. The firm has a market cap of $349.80 million, a PE ratio of -14.46 and a beta of 0.69. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $6.92 and a fifty-two week high of $20.90. The business’s fifty day moving average is $10.91 and its two-hundred day moving average is $12.26.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the company posted ($0.18) earnings per share. Equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.66 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on YMAB shares. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.